Premium
Misoprostol for prevention and treatment of postpartum hemorrhage: What do we know? What is next?
Author(s) -
Raghavan Sheila,
Abbas Dina,
Winikoff Beverly
Publication year - 2012
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2012.03.013
Subject(s) - misoprostol , uterotonic , medicine , shivering , adverse effect , obstetrics , randomized controlled trial , oxytocin , anesthesia , pregnancy , surgery , abortion , genetics , biology
Misoprostol is an effective and safe uterotonic for the prevention and treatment of postpartum hemorrhage (PPH). A 600‐μg oral dose of misoprostol has been shown to prevent PPH in community‐based randomized controlled trials. An 800‐μg sublingual dose of misoprostol appears to be a good first‐line treatment for controlling PPH. Adverse effects after use of misoprostol for PPH prevention or treatment may include shivering and fever. These effects are transient, resolve on their own, and are not life threatening. Misoprostol can play an important role in settings with limited access to oxytocin, and where there is no other option for PPH care.